Matching Therapies by Comparison of Kinase ATP Uptake in Lung Tumors and Drug Responses in Lung Cancer Cell Lines

摘要

1. ABPP-and pY-LC-MRM platforms have been evaluated and detect dominant signaling phenotypes in NSCLC tumors and cell lines. 2. ABPP/pY profiles can direct treatment strategies, as shown in vitro. 3. ABPP-LC-MRM elucidates global inhibitor effects and potential drug resistance mechanisms. 4. Ongoing Experiments: a. ABPP analysis of additional adenocarcinoma samples. b. Optimization of pY-LC-MRM for small amounts (1mg) of tumor tissue. c. Integration of the squamous cell carcinoma and adenocarcinoma data. d. Cell line drug treatment studies including clinically available inhibitors. (e.g. Dasatinib, Lapatinib, Ponatinib, Trametinib, and BEZ-235).